Eli Lilly beats Novo Nordisk to China approval for first oral GLP-1 weight-loss drug
China has approved US pharmaceutical giant Eli Lilly’s weight-loss pill orforglipron, making it the country’s first available oral GLP-1 treatment for obesity as global drug makers seek to tap the country’s massive weight-management market. China’s National Medical Products Administration announced the approval on Thursday, saying that the once-daily pill, marketed as Foundayo, could be used for…
We haven't written up this one. SCMP Business has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.
